Century Therapeutics Reports Q3 2026 Loss of $23.5 Million, Cash of $174.1 Million

Century Therapeutics reported a Q3 2026 net loss of $23.5M, narrower than the $34.4M loss in Q3 2025. R&D expenses fell to $18.1M, and cash reserves totaled $174.1M. The company expects its cash runway to extend into Q1 2029. CNTY-813, a diabetes therapy, is on track for an IND submission in Q4 2026, with initial data expected in H2 2027. CNTY-308, a CAR-iT cell therapy, is set to enter clinical testing in 2026. Joseph Truitt joined the board of directors.

Original reporting
Published Nov 12, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Century Therapeutics Reports Q3 2026 Loss of $23.5 Million, Cash of $174.1 Million — source image
Decision brief

The 30-second read

$CNTYBullishMed
01

Why it matters

The earnings beat on loss reduction and cash increase may attract short‑term buying interest.

02

Market read

Primary earnings disclosure for a micro‑cap biotech, modest trading relevance.

03

What to watch

Upcoming IND filing for CNTY-813 and entry of CNTY-308 into clinical testing could drive future volatility.

Relevance 6/10Novelty 6/10Timing: post‑market today

Background

Century Therapeutics filed an 8‑K reporting its Q3 2026 results and pipeline updates.

Company-level read

Ticker impact

$CNTYBullishMedium confidence
Context

Quarterly earnings release showing Q3 2026 net loss of $23.5M and cash runway to Q1 2029.

Expected impact

likely modest upside as loss narrowed and cash position improved

Evidence & confidence

Investors may view reduced loss and higher cash as a positive trend, supporting a short-term price gain.

Market effects

Biotech sector may see slight sentiment lift from improved cash runway.

US biotech investors could adjust positions modestly.

Limited to niche biotech investors.

Counterpoint

Loss narrowing may be priced in; risk of further dilution or unmet milestones could pressure the stock.

Key entities

  • Century Therapeutics

    US‑listed biotech (ticker CNTY) reporting Q3 2026 results.

Related articles

$CNTYMed

Century Casinos Considers Selling Alberta Assets

Century Casinos Co-CEO Peter Hoetzinger said the company is considering selling its Canadian properties and its majority stake in Casinos Poland. Alberta assets could be sold as one package or split into commercial casinos and racinos. Century reported Q2 net operating revenue of $152m, adjusted EBITDAR $31.7m, and a $10.9m shareholder net loss. The review aims to reduce debt and improve value.

$CNTYMed

Century Casinos, Inc. Q2 2026 Earnings Call Summary

Century Casinos, Inc. reported Q2 2026 all-time record revenue and EBITDA, citing a 12% EBITDA rise in North America, now about 90% of total results. Management attributed gains to recent capital investment “contribution phase,” with strong Nugget and Missouri performance. It expects net debt-to-EBITDA below 6x by year-end 2026, supported by lower CapEx and cash flow, while noting Poland and Alberta risks.

$CNTYMedAI 8/10

Century Casinos, Inc. Announces Second Quarter 2026 Results

Century Casinos, Inc. (Nasdaq: CNTY) reported Q2 2026 results for the three and six months ended June 30, 2026. Net operating revenue rose 1% to $152.0 million, and earnings from operations rose 4% to $17.2 million. Adjusted EBITDAR increased 5% to $31.7 million. Cash was $60.2 million and outstanding debt $336.5 million as of June 30, 2026.

$CNTYMed

Why is Century Casinos stock climbing today?

Century Casinos (CNTY) shares rose about 4.2% pre-open after the company reported Q2 2026 results. Net operating revenue was $152.0 million (+1% YoY), earnings from operations $17.2 million (+4%), and Adjusted EBITDAR $31.7 million (+5%). First-half revenue was $289.2 million (+3%) and Adjusted EBITDAR $56.6 million (+12%). Cash was $60.2 million versus $336.5 million debt.

$CNTYMed

Century Casinos, Inc. Announces Second Quarter 2026 Results

CENTURY CASINOS INC /CO/ (CNTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. PRESS RELEASE August 7, 2026 Century Casinos, Inc. Announces Second Quarter 202 6 Results All-Time Record Q2 Net Operating Revenue and Adjusted EBITDAR, Driven by Strong Performance in North America.  Colorado Springs, Colorado – August 7, 2026 – Century Casinos, Inc. (the “Comp

$TEOMedAI 8/10

Telecom Argentina Stet - France Telecom Q3 Earnings Call Highlights

Telecom Argentina (NYSE:TEO) reported Q3 capital expenditures of $350M, with net debt decreasing 9% YoY to $2.9B. 5G sites expanded to 1,900. Postpaid mobile lines grew 1% YoY, broadband increased 2.5%, and pay TV grew nearly 5%. EBITDA margin excluding TMA exceeded 42%. The company agreed to a $400M divestment with Metrotel, aiming for future integration.